Biomarker Detection of Lung Cancers Before Clinical Symptoms or the Use of Traditional Imaging Methods in the ITALUNG Trial.
Int J Mol SciSep 20, 2026 (epub)
Simonetta Bisanzi, Valentina Russo, Laura Carrozzi et al.
✦ AI-curated · Sources linked
In 30 seconds
The ITALUNG trial, a randomized controlled trial, assessed the efficacy of Low-Dose Computed Tomography (LDCT) for lung cancer screening in over 3100 high-risk individuals aged 55-69. The study found that the ITALUNG biomarker panel demonstrated a sensitivity of 90% at baseline screening, with 95% sensitivity for lung cancer cases identified close to diagnosis, highlighting the potential of biomarkers in early detection.
Key findings
- The ITALUNG biomarker panel showed 95% sensitivity for lung cancer cases identified close to diagnosis.
- Out of 21 lung cancer cases, 20 were positive in the ITALUNG biomarker panel.
- The panel identified over 80% of lung cancer cases from pre-diagnostic samples collected within 3 years prior to diagnosis.
- Over 67% of early and resected cancer cases were detected when samples were obtained within 11 years prior to diagnosis.
Why it matters
This study underscores the importance of early detection of lung cancer, which can significantly impact treatment outcomes. The potential use of biomarkers alongside imaging may enhance screening strategies for high-risk populations.